Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Astellas Pharma Inc
Mayo Clinic
Bristol-Myers Squibb
Genmab
Jazz Pharmaceuticals
Myeloid Therapeutics
Avacta Life Sciences Ltd
Ocellaris Pharma, Inc.
Innate Pharma
Mayo Clinic
Tanabe Pharma America, Inc.
ITM Oncologics GmbH
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
Exelixis
Incyte Corporation
Jonsson Comprehensive Cancer Center
Xencor, Inc.
NuCana plc
University of Virginia
NextPoint Therapeutics, Inc.
Affiliated Hospital of Jiangnan University
Affiliated Hospital of Jiangnan University
UNICANCER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Monopar Therapeutics
Monopar Therapeutics
Klus Pharma Inc.
Orion Biotechnology Polska Sp. z o.o.
Daiichi Sankyo
RAPT Therapeutics, Inc.
Cybrexa Therapeutics
Carisma Therapeutics Inc
Zumutor Biologics Inc.
Salubris Biotherapeutics Inc
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Xencor, Inc.
Pliant Therapeutics, Inc.
NextCure, Inc.
Universitair Ziekenhuis Brussel
Fate Therapeutics
Fred Hutchinson Cancer Center
OncoNano Medicine, Inc.
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Nektar Therapeutics
Institut Bergonié
Herlev Hospital